Buket Mermi̇t

Dr. Buket Mermi̇t

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Infectious Diseases Now
Verified
Journal Article
Closed access
HYHanifi YILDIZ
Hanifi YILDIZ
HAHamit Hakan Alp
Hamit Hakan Alp
SESelami Ekin
Selami Ekin
AAAhmet Arisoy
Ahmet Arisoy
HGHulya Gunbatar
Hulya Gunbatar
MHMine Haylu
Mine Haylu

8 August 2020 in The Clinical Respiratory Journal
Verified
Journal Article
Closed access
PDF file
BMBuket Mermi̇t
Buket Mermi̇t
HGHülya Günbatar
Hülya Günbatar
VÇVedat Çilingir
Vedat Çilingir

1 September 2015 in Dicle Tıp Dergisi
Verified
Journal Article
Open access
PDF file
HGHülya Günbatar
Hülya Günbatar
SESelami Ekin
Selami Ekin
ASAysel Sünnetçioğlu
Aysel Sünnetçioğlu
AAAhmet Arısoy
Ahmet Arısoy
BMBuket Mermi̇t
Buket Mermi̇t
BSBünyamin Sertoğullarından
Bünyamin Sertoğullarından
The relationship between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with obstructive sleep apnea syndrome

1 January 2022 in Clinical Laboratory
Verified
Journal Article
Closed access
BMBuket Mermi̇t
Buket Mermi̇t
SASelvi Askar
Selvi Askar
AMAyfer Meral
Ayfer Meral
MAMuntecep Askar
Muntecep Askar
Background: COVID-19 has continued to aggressively spread and kill. The incidence of complications and associated mortality rates are high. Cardiac damage, which is related to survival, is one of these. The purpose of this study is to assess the role of BNP, a cardiac biomarker, in predicting mortality in COVID-19. Materials and Methods: This single-center, prospective observational study was performed from July to September 2020 in a tertiary university hospital designated for the treatment of COVID-19 patients. Patients whose diagnoses were confirmed with real-time polymerase chain reaction (RT-PCR) tested nasopharyngeal swabs and with thoracic computed tomography (CT) findings compatible with COVID-19 pneumonia were included in the study. All clinical and laboratory data were obtained within the first 24 hours of hospital admission. To determine the risk of in-hospital death, patients were followed from admission until their discharge (1 to 15 days). The primary outcome was in-hospital death, defined as the case-fatality ratio. Results: Among all biomarkers that were included in the multivariate analysis only high BNP levels was independently associated with mortality [Mean 1.012, 95% CI (1.005 -1.02 pg/mL) (p = 0.002)]. Mortality was found to be significantly associated with older age and higher BNP, LDH, AST, HGB, PLT, ferritin, D-dimer, and CRP levels. In addition, mortality was found to be higher with longer duration of hospitalization (p = 0.041). Conclusions: Our fundamental goal for COVID-19 is to determine whether the hospitalized patients are in the mortality risk group at an early stage of disease. Adding measurement of BNP levels to routine laboratory tests for COVID-19 may be a practical approach to determine the patients with a high risk of mortality. (Clin. Lab. 2022;68:xx-xx. DOI: 10.7754/Clin.Lab.2021.210602)

7 May 2021
Verified
Book
Closed access
PDF file
SÖSevda Ünallı Özmen
Sevda Ünallı Özmen
EKEsra Meltem Koç
Esra Meltem Koç
HAHilal Aksoy
Hilal Aksoy
MÖMikail Özdemir
Mikail Özdemir
AAAysun Albayrak
Aysun Albayrak
SASüleyman Agüloğlu
Süleyman Agüloğlu
Saygıdeğer okuyucular,Her şeyden önce size teşekkür etmek istiyorum, bilgi çağında, bilgiden yoksun, bilgiden uzak işini yapadurmak yerine, sağlık alanındaki inovasyon, teknoloji ve yapay zeka kulvarlarındaki merakınız ve hekimseniz hastanıza en doğru tanıyı koyup, en doğru tedaviyi vermek gayesi yada alan uzmanı iseniz de bu alanlarda gelişime inanarak okumayı seçtiğiniz, konfor alanınızı bozmayı kabul ettiğiniz için.Bu kitapta sağlığımızın geleceğinin büyük bir kısmını oluşturacak olan, sağlığın yapay zekasını size sunduk. Yapay zekanın sağlık alanındaki gelişmelerini, karar destek sistemlerini, büyük veriyi ve gelecek perspektifini en güncel bilgiler ışığında bu kitapta bulacaksınız.

12 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NKNagihan Durmuş Koçak
Nagihan Durmuş Koçak
NTNuri Tutar
Nuri Tutar
GÇGizem Çil
Gizem Çil
EAEmine Afşin
Emine Afşin
AŞAyşegül Şentürk
Ayşegül Şentürk
APAyşe Pala
Ayşe Pala
Background/Objectives: The association between past coronavirus disease-19 (COVID-19) infection and pulmonary thromboembolism (PTE) is a potential research topic. We aimed to research the prevalence of previous COVID-19 infection in patients with PTE and to determine whether there is a difference in embolism severity in these cases. Methods: Study design: Multicenter, observational, cross-sectional. Patients diagnosed with PTE between 11 March 2022 and 11 March 2023 were prospectively included in this study, excluding cases with PTE along with active COVID-19, patients under the age of 18, and pregnant patients. Group 1 consisted of PTE cases with previous COVID-19, and Group 2 consisted of PTE cases without previous COVID-19. Key variables are D-Dimer level, right ventricle/left ventricle (RV/LV) ratio, simplified pulmonary embolism severity score, and treatment type. Results: A total of 1185 patients (Group 1; n = 360, Group 2; n = 825) were included in this study. The proportion of patients with RV/LV ratio > 1 on computed tomography pulmonary angiography (CTPA) was significantly high in Group 2 compared to Group 1 (27.9% vs. 19.7%, p = 0.003). In multivariate logistic regression analysis, the absence of any identifiable risk factor for PTE was found to be a 0.46-fold protective factor in the presence of previous COVID-19 (OR: 0.456 95% CI: 0.274–0.760, Wald = 9.070, df = 1, p = 0.003) and an RV/LV ratio > 1 on CTPA was found to be a 0.60-fold protective factor (OR: 0.603, 95% CI: 0.365–0.998, Wald = 3.874, df = 1, p = 0.049). Conclusions: The prevalence of previous COVID-19 infection in PTE cases was 30.4%, and 26.3% of idiopathic cases had previous COVID-19 infection. Although the parameters related to embolism severity were higher in the non-COVID-19 group, multivariate analyses revealed a 2.2-fold increased risk for idiopathic PTE and a 1.7-fold increased risk for RV/LV ratio > 1 on CTPA in patients without COVID-19 compared to those with prior COVID-19.